{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:04:50Z","timestamp":1789736690702,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008871","name":"Juvenile Diabetes Research Foundation United States of America","doi-asserted-by":"publisher","award":["3-SRA-2024-1487-S-B"],"award-info":[{"award-number":["3-SRA-2024-1487-S-B"]}],"id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["455203589"],"award-info":[{"award-number":["455203589"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001663","name":"Volkswagen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For many autoimmune diseases, including type 1 diabetes mellitus (T1DM), efforts have been made to modify the disease process through pharmacotherapy. The ultimate goal must be to develop therapies with curative potential by achieving an organ without signs of parenchymal cell destruction and without signs of immune cell infiltration. In the case of the pancreas, this means regenerated and well-preserved beta cells in the islets without activated infiltrating immune cells. Recent research has opened up the prospect of successful antibody combination therapy for autoimmune diabetes with curative potential. This goal cannot be achieved with monotherapies. The requirements for the implementation of such a therapy with curative potential for the benefit of patients with T1DM and LADA (latent autoimmune diabetes in adults) are considered.<\/jats:p>","DOI":"10.1007\/s00109-024-02494-w","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T02:02:07Z","timestamp":1729216927000},"page":"1451-1455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapy concepts in type 1 diabetes mellitus treatment: disease modifying versus curative approaches"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2125-8193","authenticated-orcid":false,"given":"Sigurd","family":"Lenzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"J\u00f6rns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"2494_CR1","volume-title":"Glory enough for all","author":"M Bliss","year":"1982","unstructured":"Bliss M (1982) Glory enough for all. McClelland and Stewart, Toronto"},{"key":"2494_CR2","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.2174\/156802606778194217","volume":"6","author":"K Chatzantoni","year":"2006","unstructured":"Chatzantoni K, Mouzaki A (2006) Anti-TNF-alpha antibody therapies in autoimmune diseases. Curr Top Med Chem 6:1707\u20131714","journal-title":"Curr Top Med Chem"},{"key":"2494_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zheng Y, Chen X (2017) Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 8:460","journal-title":"Front Pharmacol"},{"key":"2494_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M (2015) Anti-TNF therapy: past, present and future. Int Immunol 27:55\u201362","journal-title":"Int Immunol"},{"key":"2494_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1756283X13479826","volume":"6","author":"GR Lichtenstein","year":"2013","unstructured":"Lichtenstein GR (2013) Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 6:269\u2013293","journal-title":"Therap Adv Gastroenterol"},{"key":"2494_CR6","first-page":"35","volume":"30","author":"S Chaplin","year":"2019","unstructured":"Chaplin S (2019) Monoclonal antibodies for the treatment of plaque psoriasis. Prescriber 30:35\u201340","journal-title":"Prescriber"},{"key":"2494_CR7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y (2020) Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: literature review. Int J Mol Sci 21:1690","journal-title":"Int J Mol Sci"},{"key":"2494_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/1759720X17720366","volume":"9","author":"S Ajeganova","year":"2017","unstructured":"Ajeganova S, Huizinga T (2017) Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis 9:249\u2013262","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2494_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2337\/db19-0865","volume":"69","author":"A J\u00f6rns","year":"2020","unstructured":"J\u00f6rns A, Wedekind D, J\u00e4hne J, Lenzen S (2020) Pancreas pathology of latent autoimmune diabetes in adults (LADA) in patients and in a LADA rat model compared with type 1 diabetes. Diabetes 69:624\u2013633","journal-title":"Diabetes"},{"key":"2494_CR10","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ecl.2010.05.009","volume":"39","author":"LY Melendez-Ramirez","year":"2010","unstructured":"Melendez-Ramirez LY, Richards RJ, Cefalu WT (2010) Complications of type 1 diabetes. Endocrinol Metab Clin North Am 39:625\u2013640","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2494_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/dia.2019.0398","volume":"22","author":"M Sussman","year":"2020","unstructured":"Sussman M, Benner J, Haller MJ, Rewers M, Griffiths R (2020) Estimated lifetime economic burden of type 1 diabetes. Diabetes Technol Ther 22:121\u2013130","journal-title":"Diabetes Technol Ther"},{"key":"2494_CR12","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/ijms21051598","volume":"21","author":"J Ludvigsson","year":"2020","unstructured":"Ludvigsson J (2020) Autoantigen treatment in type 1 diabetes: unsolved questions on how to select autoantigen and administration route. Int J Mol Sci 21:1598","journal-title":"Int J Mol Sci"},{"key":"2494_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11892-019-1144-3","volume":"19","author":"GLL Xin","year":"2019","unstructured":"Xin GLL, Khee YP, Ying TY et al (2019) Current status on immunological therapies for type 1 diabetes mellitus. Curr Diab Rep 19:22","journal-title":"Curr Diab Rep"},{"key":"2494_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/MOP.0000000000000504","volume":"29","author":"ML Marcovecchio","year":"2017","unstructured":"Marcovecchio ML, Chiarelli F (2017) Pharmacotherapy options for pediatric diabetes. Curr Opin Pediatr 29:481\u2013487","journal-title":"Curr Opin Pediatr"},{"key":"2494_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1365-2249.2010.04153.x","volume":"160","author":"JB Matthews","year":"2010","unstructured":"Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M, Group I-JTDCTA (2010) Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160:176\u2013184","journal-title":"Clin Exp Immunol"},{"key":"2494_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1055\/s-0030-1253678","volume":"135","author":"NC Schloot","year":"2010","unstructured":"Schloot NC (2010) Immunological intervention to preserve beta-cell function in type 1 diabetes. Dtsch Med Wochenschr 135:915\u2013921","journal-title":"Dtsch Med Wochenschr"},{"key":"2494_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/imt.10.23","volume":"2","author":"M von Herrath","year":"2010","unstructured":"von Herrath M (2010) Combination therapies for type 1 diabetes: why not now? Immunotherapy 2:289\u2013291","journal-title":"Immunotherapy"},{"key":"2494_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.clim.2013.02.003","volume":"149","author":"GT Nepom","year":"2013","unstructured":"Nepom GT, Ehlers M, Mandrup-Poulsen T (2013) Anti-cytokine therapies in T1D: concepts and strategies. Clin Immunol 149:279\u2013285","journal-title":"Clin Immunol"},{"key":"2494_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.imlet.2014.02.006","volume":"159","author":"J Ludvigsson","year":"2014","unstructured":"Ludvigsson J (2014) Combination therapy for preservation of beta cell function in type 1 diabetes: new attitudes and strategies are needed! Immunol Lett 159:30\u201335","journal-title":"Immunol Lett"},{"key":"2494_CR20","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4161\/hv.26890","volume":"10","author":"AK Ryden","year":"2014","unstructured":"Ryden AK, Wesley JD, Coppieters KT, Von Herrath MG (2014) Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother 10:838\u2013846","journal-title":"Hum Vaccin Immunother"},{"key":"2494_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S2213-8587(18)30112-8","volume":"7","author":"MA Atkinson","year":"2019","unstructured":"Atkinson MA, Roep BO, Posgai A, Wheeler DCS, Peakman M (2019) The challenge of modulating beta-cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol 7:52\u201364","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2494_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-0716-0385-7_5","volume":"2128","author":"S Lenzen","year":"2020","unstructured":"Lenzen S, Arndt T, Elsner M, Wedekind D, J\u00f6rns A (2020) Rat models of human type 1 diabetes. Methods Mol Biol 2128:69\u201385","journal-title":"Methods Mol Biol"},{"key":"2494_CR23","doi-asserted-by":"crossref","unstructured":"J\u00f6rns A, Arndt T, Meyer zu Vilsendorf A, et al. (2014) Islet infiltration, cytokine expression and beta cell death in the NOD mouse, BB rat, Komeda rat, LEW.1AR1-iddm rat and humans with type 1 diabetes. Diabetologia 57:512-521","DOI":"10.1007\/s00125-013-3125-4"},{"key":"2494_CR24","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.2337\/db14-1866","volume":"64","author":"A J\u00f6rns","year":"2015","unstructured":"J\u00f6rns A, Ertekin \u00dcG, Arndt T, Terbish T, Wedekind D, Lenzen S (2015) TNF-alpha antibody therapy in combination with the T-cell-specific antibody anti-TCR reverses the diabetic metabolic state in the LEW.1AR1-iddm rat. Diabetes 64:2880\u20132891","journal-title":"Diabetes"},{"key":"2494_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2337\/dc22-0908","volume":"46","author":"MR Rigby","year":"2023","unstructured":"Rigby MR, Hayes B, Li Y, Vercruysse F, Hedrick JA, Quattrin T (2023) Two-year follow-up from the T1GER study: continued off-therapy metabolic improvements in children and young adults with new-onset T1D treated with golimumab and characterization of responders. Diabetes Care 46:561\u2013569","journal-title":"Diabetes Care"},{"key":"2494_CR26","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1001\/jama.2011.878","volume":"305","author":"DH Solomon","year":"2011","unstructured":"Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S (2011) Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305:2525\u20132531","journal-title":"JAMA"},{"key":"2494_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/acr.20657","volume":"64","author":"JL Antohe","year":"2012","unstructured":"Antohe JL, Bili A, Sartorius JA et al (2012) Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor alpha therapy. Arthritis Care Res (Hoboken) 64:215\u2013221","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2494_CR28","first-page":"743","volume":"92","author":"A J\u00f6rns","year":"2014","unstructured":"J\u00f6rns A, Akin M, Arndt T et al (2014) Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by beta cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes. J Mol Med (Berl) 92:743\u2013755","journal-title":"J Mol Med (Berl)"},{"key":"2494_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00109-020-01941-8","volume":"98","author":"A J\u00f6rns","year":"2020","unstructured":"J\u00f6rns A, Arndt T, Yamada S et al (2020) Translation of curative therapy concepts with T cell and cytokine antibody combinations for type 1 diabetes reversal in the IDDM rat. J Mol Med (Berl) 98:1125\u20131137","journal-title":"J Mol Med (Berl)"},{"key":"2494_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/eji.1830230216","volume":"23","author":"S Bolt","year":"1993","unstructured":"Bolt S, Routledge E, Lloyd I et al (1993) The generation of a humanized, non-mitogenic Cd3 monoclonal-antibody which retains in vitro immunosuppressive properties. Eur J Immunol 23:403\u2013411","journal-title":"Eur J Immunol"},{"key":"2494_CR31","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nri2134","volume":"7","author":"L Chatenoud","year":"2007","unstructured":"Chatenoud L, Bluestone JA (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 7:622\u2013632","journal-title":"Nat Rev Immunol"},{"key":"2494_CR32","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2174\/1871530320999201209222921","volume":"21","author":"AZ Nourelden","year":"2021","unstructured":"Nourelden AZ, Elshanbary AA, El-Sherif L et al (2021) Safety and efficacy of teplizumab for treatment of type one diabetes mellitus: A systematic review and meta-analysis. Endocr Metab Immune Disord Drug Targets 21:1895\u20131904","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2494_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(11)60980-X","volume":"378","author":"JF Bach","year":"2011","unstructured":"Bach JF (2011) Anti-CD3 antibodies for type 1 diabetes: beyond expectations. Lancet 378:459\u2013460","journal-title":"Lancet"},{"key":"2494_CR34","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMoa012864","volume":"346","author":"KC Herold","year":"2002","unstructured":"Herold KC, Hagopian W, Auger JA et al (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692\u20131698","journal-title":"N Engl J Med"},{"key":"2494_CR35","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMoa043980","volume":"352","author":"B Keymeulen","year":"2005","unstructured":"Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598\u20132608","journal-title":"N Engl J Med"},{"key":"2494_CR36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","volume":"53","author":"B Keymeulen","year":"2010","unstructured":"Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614\u2013623","journal-title":"Diabetologia"},{"key":"2494_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","volume":"378","author":"N Sherry","year":"2011","unstructured":"Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487\u2013497","journal-title":"Lancet"},{"key":"2494_CR38","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.2337\/db13-0236","volume":"62","author":"W Hagopian","year":"2013","unstructured":"Hagopian W, Ferry RJ Jr, Sherry N et al (2013) Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes 62:3901\u20133908","journal-title":"Diabetes"},{"key":"2494_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"KC Herold","year":"2019","unstructured":"Herold KC, Bundy BN, Long SA et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381:603\u2013613","journal-title":"N Engl J Med"},{"key":"2494_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00125-018-4786-9","volume":"62","author":"AL Perdigoto","year":"2019","unstructured":"Perdigoto AL, Preston-Hurlburt P, Clark P et al (2019) Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 62:655\u2013664","journal-title":"Diabetologia"},{"key":"2494_CR41","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3390\/ijms21062103","volume":"21","author":"N Rapini","year":"2020","unstructured":"Rapini N, Schiaffini R, Fierabracci A (2020) Immunotherapy strategies for the prevention and treatment of distinct stages of type 1 diabetes: an overview. Int J Mol Sci 21:2103","journal-title":"Int J Mol Sci"},{"key":"2494_CR42","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00125-020-05376-1","volume":"64","author":"R Assfalg","year":"2021","unstructured":"Assfalg R, Knoop J, Hoffman KL et al (2021) Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial. Diabetologia 64:1079\u20131092","journal-title":"Diabetologia"},{"key":"2494_CR43","doi-asserted-by":"publisher","first-page":"712870","DOI":"10.3389\/fimmu.2021.712870","volume":"12","author":"I Serr","year":"2021","unstructured":"Serr I, Drost F, Schubert B, Daniel C (2021) Antigen-specific T reg therapy in type 1 diabetes - challenges and opportunities. Front Immunol 12:712870","journal-title":"Front Immunol"},{"key":"2494_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1159\/000524866","volume":"96","author":"D SmigocSchweiger","year":"2023","unstructured":"SmigocSchweiger D (2023) Recent advances in immune-based therapies for type 1 diabetes. Horm Res Paediatr 96:631\u2013645","journal-title":"Horm Res Paediatr"},{"key":"2494_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cmet.2019.11.017","volume":"31","author":"JT Warshauer","year":"2020","unstructured":"Warshauer JT, Bluestone JA, Anderson MS (2020) New frontiers in the treatment of type 1 diabetes. Cell Metab 31:46\u201361","journal-title":"Cell Metab"},{"key":"2494_CR46","doi-asserted-by":"publisher","first-page":"1076343","DOI":"10.3389\/fendo.2023.1076343","volume":"14","author":"S Dalle","year":"2023","unstructured":"Dalle S, Abderrahmani A, Renard E (2023) Pharmacological inhibitors of beta-cell dysfunction and death as therapeutics for diabetes. Front Endocrinol (Lausanne) 14:1076343","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2494_CR47","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1089\/dia.2020.0305","volume":"22","author":"LM Jacobsen","year":"2020","unstructured":"Jacobsen LM, Bundy BN, Greco MN et al (2020) Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Tech Therap 22:948\u2013953","journal-title":"Diabetes Tech Therap"},{"key":"2494_CR48","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2337\/dc17-0806","volume":"41","author":"PJ Bingley","year":"2018","unstructured":"Bingley PJ, Wherrett DK, Shultz A, Rafkin LE, Atkinson MA, Greenbaum CJ (2018) Type 1 Diabetes TrialNet: a multifaceted approach to bringing disease-modifying therapy to clinical use in type 1 diabetes. Diabetes Care 41:653\u2013661","journal-title":"Diabetes Care"},{"key":"2494_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00125-023-06014-2","volume":"67","author":"C Mathieu","year":"2024","unstructured":"Mathieu C, Wiedeman A, Cerosaletti K et al (2024) A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab. Diabetologia 67:27\u201341","journal-title":"Diabetologia"},{"key":"2494_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12916-020-1503-6","volume":"18","author":"A J\u00f6rns","year":"2020","unstructured":"J\u00f6rns A, Ishikawa D, Teraoku H, Yoshimoto T, Wedekind D, Lenzen S (2020) Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or\/and anti-IL-6 in the IDDM rat model of type 1 diabetes. BMC Med 18:33","journal-title":"BMC Med"},{"key":"2494_CR51","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.2337\/dc23-0675","volume":"46","author":"KC Herold","year":"2023","unstructured":"Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL (2023) Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves beta-cell function. Diabetes Care 46:1848\u20131856","journal-title":"Diabetes Care"},{"key":"2494_CR52","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1210\/en.2010-0202","volume":"151","author":"A J\u00f6rns","year":"2010","unstructured":"J\u00f6rns A, Rath KJ, Terbish T et al (2010) Diabetes prevention by immunomodulatory FTY720 treatment in the LEW.1AR1-iddm rat despite immune cell activation. Endocrinology 151:3555\u20133565","journal-title":"Endocrinology"},{"key":"2494_CR53","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1126\/science.abh1654","volume":"373","author":"JA Bluestone","year":"2021","unstructured":"Bluestone JA, Buckner JH, Herold KC (2021) Immunotherapy: building a bridge to a cure for type 1 diabetes. Science 373:510\u2013516","journal-title":"Science"},{"key":"2494_CR54","doi-asserted-by":"publisher","unstructured":"Sims EK, Bundy BN, Stier K, et al (2021) Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 13: eabc 8980. https:\/\/doi.org\/10.1126\/scitranslmed.abc8980","DOI":"10.1126\/scitranslmed.abc8980"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02494-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-024-02494-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02494-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:40:34Z","timestamp":1732095634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-024-02494-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2494"],"URL":"https:\/\/doi.org\/10.1007\/s00109-024-02494-w","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}